Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12324738 | 1.00 | LMNA (0.41) | LMNACES2USP2NPSR1 | |
| SCHEMBL2422397 | 0.81 | LMNA (0.33) | LMNACES2 | |
| SCHEMBL2424472 | 0.80 | OSBP (0.34) | LMNACES2 | |
| SCHEMBL2424856 | 0.77 | LMNA (0.31) | LMNA | |
| SCHEMBL12324739 | 0.77 | NR3C1 (0.33) | LMNA | |
| SCHEMBL2422370 | 0.75 | CYP3A4 (0.39) | LMNA | |
| SCHEMBL2424376 | 0.71 | — | — | |
| SCHEMBL2425831 | 0.71 | CYP3A4 (0.34) | LMNA | |
| SCHEMBL31178438 | 0.71 | USP2 (0.38) | LMNAUSP2NPSR1 | |
| SCHEMBL2422520 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445732-B2 | Organic compounds | GIVAUDAN SA (CH) | 2013-05-21 | — | — | US | claimed |
| EP-2252674-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-09-07 | — | — | EP | claimed |
| US-20100331427-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-12-30 | — | — | US | claimed |
| EP-2252674-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-11-24 | — | — | EP | claimed |
| WO-2009100554-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-08-20 | — | — | WO | claimed |
| US-8445732-B2 | Organic compounds | GIVAUDAN SA (CH) | 2013-05-21 | — | — | US | disclosed |
| EP-2252674-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-09-07 | — | — | EP | disclosed |
| US-20100331427-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-12-30 | — | — | US | disclosed |
| EP-2252674-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009100554-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331427-A1 | Organic Compounds | C9, C5, CBR3 | LMNA 3019/4885CES2 465/4885USP2 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.